Research analysts at HC Wainwright lowered their Q1 2025 EPS estimates for Genelux in a report released on Monday, March 31st ...

Equities researchers at HC Wainwright issued their FY2029 earnings estimates for shares of Daré Bioscience in a research note ...

Fintel reports that on April 3, 2025, HC Wainwright & Co. initiated coverage of Kairos Pharma (NYSEAM:KAPA) with a Buy ...

Fintel reports that on April 2, 2025, HC Wainwright & Co. upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) ...

H.C. Wainwright analyst Douglas Tsao views the agreement of joint stipulation between Arcutis Biotherapeutics (ARQT) and Padagis to the ongoing ...

H.C. Wainwright lowered the firm’s price target on Kyverna Therapeutics (KYTX) to $4 from $6 and keeps a Neutral rating on the shares following ...

Sarepta and Roche paused Elevidys trials in the EU after a patient death. Analysts warn of potential sales declines as safety concerns impact market outlook.

A webcast replay will be available on the VYNE website for 90 days following the event. About VYNE Therapeutics Inc. VYNE is a clinical-stage biopharmaceutical company focused on developing ...

Fintel reports that on March 31, 2025, HC Wainwright & Co. initiated coverage of Virax Biolabs Group (NasdaqCM:VRAX) with a Buy recommendation. As of January 19, 2024, the average one-year price ...

NEW YORK, April 01, 2025--(BUSINESS WIRE)--H.C. Wainwright & Co., LLC ("HCW") announces a significant milestone, securing its #1 ranking for the 40th consecutive quarter in PlacementTracker’s ...